The Effect of Aripiprazole on Smoking Rate in Schizophrenic Patients

A Comparision Between Effect of Aripiprazole and Placebo on the Rate of Nicotine Dependence in Schizophrenic patients

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2013010512018N1

Enrollment

Registered

2013-04-06

Start date

2013-04-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. The schizophrenic disorders are characterized in general by fundamental and characteristic distortions of thinking and perception, and affects that are inappropriate or blunted. Clear consciousness and intellectual capacity are usually maintained although

Interventions

Intervention 1: intervention group: tablet Aripiprazole, 10 mg, once daily, for 6 weeks. Intervention 2: control group: placebo, one tablet daily, for 6 weeks.

Treatment - Drugs

Placebo

intervention group: tablet Aripiprazole, 10 mg, once daily, for 6 weeks

control group: placebo, one tablet daily, for 6 weeks

Eligibility

Sex/Gender

Male

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: diagnosis of schizophrenia according to DSM IV TR criteria using semi-structured interviews,being in partial or complete remission phase, having necessary criteria for the diagnosis of nicotine dependence criteria according to DSM IV TR, aged 18 – 60 years, male sex. exclusion Criteria: a history of allergy or any side effect due to Aripiprazole or other antipsychotics, dependency to other substances (based on the patient's history and morphine and methamphetamine test results at the time of intervention), comorbidity of the other major psychiatric disorders (such as unipolar and bipolar mood disorders), use of other drugs used for nicotine withdrawal, active phase of psychosis.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
The rate of nicotine dependence. Timepoint: befor intervention and 6 weeks after intervention. Method of measurement: Nicotine Dependence Questionnaire (FAGERSTROM).	—

Secondary

Measure	Time frame
Extrapyramidal side effects. Timepoint: befor intervention and 6 weeks after intervention. Method of measurement: abnormal involuntary movement scale.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAsghar Arfaie

Tabriz university of medical sciences

arfaia@tbzmed.ac.ir+98 41 1380 3353

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 5, 2026